Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial - PubMed
a day ago
- #immunotherapy
- #clinical trial
- #gastric cancer
- Camrelizumab plus CAPOX followed by camrelizumab-based maintenance showed longer overall survival compared to CAPOX alone in HER2-negative gastric or gastro-oesophageal junction adenocarcinoma.
- The study was a randomized phase 3 trial involving 885 adults across 75 hospitals in China.
- Primary endpoint was overall survival in PD-L1 positive and overall populations, with significant improvements observed in both.
- No additional survival benefit was seen when apatinib was added to camrelizumab maintenance, but higher rates of grade ≥3 adverse events occurred.
- Treatment-related adverse events were more frequent in the camrelizumab plus CAPOX followed by camrelizumab plus apatinib group (67.9%) compared to CAPOX alone (45.3%).